Dimethyl fumarate: targeting glycolysis to treat MS.
作者信息
Angiari Stefano, O'Neill Luke A
机构信息
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
出版信息
Cell Res. 2018 Jun;28(6):613-615. doi: 10.1038/s41422-018-0045-3.
Abstract
摘要
相似文献
1
Dimethyl fumarate: targeting glycolysis to treat MS.富马酸二甲酯：靶向糖酵解治疗多发性硬化症。
Cell Res. 2018 Jun;28(6):613-615. doi: 10.1038/s41422-018-0045-3.
2
Dimethyl Fumarate: A Review in Relapsing-Remitting MS.富马酸二甲酯：复发性多发性硬化症的综述。
Drugs. 2016 Feb;76(2):243-54. doi: 10.1007/s40265-015-0528-1.
3
Dimethyl Fumarate: A Review in Relapsing-Remitting MS.富马酸二甲酯：复发性缓解型多发性硬化症的综述。
Drugs. 2019 Dec;79(18):1965-1976. doi: 10.1007/s40265-019-01229-3.
4
Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.口服富马酸二甲酯治疗儿童多发性硬化症：一项双中心研究。
Pediatr Neurol. 2016 Apr;57:101-4. doi: 10.1016/j.pediatrneurol.2016.01.010. Epub 2016 Jan 20.
5
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.美国首发平台治疗药物转换的 MS 患者中，富马酸二甲酯与芬戈莫德和特立氟胺的疗效比较。
Mult Scler Relat Disord. 2019 Jan;27:101-111. doi: 10.1016/j.msard.2018.09.038. Epub 2018 Oct 10.
6
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.比较多发性硬化症（dimethyl fumarate、fingolimod 和 teriflunomide）口服疾病修饰疗法的临床研究结果：使用需要治疗的人数分析评估绝对差异。
Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010. Epub 2016 Nov 3.
7
Immunometabolism: Old drug, new trick.
Nat Rev Immunol. 2018 May;18(5):295. doi: 10.1038/nri.2018.29. Epub 2018 Apr 16.
8
Delayed Hypersensitivity Reaction to Oral Dimethyl Fumarate.
J Investig Allergol Clin Immunol. 2018 Jun;28(3):201-203. doi: 10.18176/jiaci.0239.
9
Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.富马酸二甲酯在多发性硬化症氧化应激中的作用：综述
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 15;1019:15-20. doi: 10.1016/j.jchromb.2016.02.010. Epub 2016 Feb 8.
10
[Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].[富马酸二甲酯治疗复发缓解型多发性硬化症]
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):68-72. doi: 10.17116/jnevro201611610268-72.
引用本文的文献
1
Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis.多发性硬化症外周免疫细胞的线粒体和代谢功能障碍。
J Neuroinflammation. 2024 Jan 20;21(1):28. doi: 10.1186/s12974-024-03016-8.
2
Neuroprotective effects of dimethyl fumarate against manic-like behavior induced by ketamine in rats.富马酸二甲酯对氯胺酮诱导的大鼠躁狂样行为的神经保护作用。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3007-3016. doi: 10.1007/s00210-023-02505-6. Epub 2023 Apr 27.
3
Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo.免疫细胞靶向富马酸酯支持 GPR109A 作为单甲基富马酸体内主要靶点的作用。
Inflammopharmacology. 2023 Jun;31(3):1223-1239. doi: 10.1007/s10787-023-01186-0. Epub 2023 Apr 1.
4
An Epigenetic Role of Mitochondria in Cancer.线粒体在癌症中的表观遗传学作用。
Cells. 2022 Aug 13;11(16):2518. doi: 10.3390/cells11162518.
5
Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise.将富马酸二甲酯用于心血管疾病的新用途：药理作用、分子机制及治疗前景
Pharmaceuticals (Basel). 2022 Apr 19;15(5):497. doi: 10.3390/ph15050497.
6
The metabolism-modulating activity of IL-17 signaling in health and disease.IL-17 信号在健康和疾病中的代谢调节活性。
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20202191.
7
COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.肥胖患者 COVID-19 严重程度：临床干预的潜在机制和分子靶点。
Obes Res Clin Pract. 2021 Mar-Apr;15(2):163-171. doi: 10.1016/j.orcp.2021.01.004. Epub 2021 Jan 19.
8
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.富马酸二甲酯治疗多发性硬化症患者的进行性多灶性脑白质病。
Mult Scler. 2022 Jan;28(1):7-15. doi: 10.1177/1352458520949158. Epub 2020 Aug 18.
9
Metabolic Regulation of Glial Phenotypes: Implications in Neuron-Glia Interactions and Neurological Disorders.胶质细胞表型的代谢调控：对神经元-胶质细胞相互作用及神经疾病的影响
Front Cell Neurosci. 2020 Feb 11;14:20. doi: 10.3389/fncel.2020.00020. eCollection 2020.
10
Nanomodulation of Macrophages in Multiple Sclerosis.多发性硬化症中的巨噬细胞的纳米调控。
Cells. 2019 Jun 5;8(6):543. doi: 10.3390/cells8060543.
本文引用的文献
1
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis.二甲基砜治疗银屑病作用机制的研究进展。
Exp Dermatol. 2018 Jun;27(6):611-624. doi: 10.1111/exd.13548. Epub 2018 Apr 25.
2
Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity.富马酸二甲酯通过靶向 GAPDH 和有氧糖酵解来调节免疫。
Science. 2018 Apr 27;360(6387):449-453. doi: 10.1126/science.aan4665. Epub 2018 Mar 29.
3
Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.衣康酸是一种抗炎代谢物，通过对 KEAP1 的烷基化作用激活 Nrf2。
Nature. 2018 Apr 5;556(7699):113-117. doi: 10.1038/nature25986. Epub 2018 Mar 28.
4
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.对富马酸二甲酯治疗多发性硬化症作用机制的新认识
Front Neurol. 2018 Jan 23;9:5. doi: 10.3389/fneur.2018.00005. eCollection 2018.
5
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.富马酸二甲酯影响多发性硬化症中的固有和适应性免疫。
J Autoimmun. 2018 Jan;86:39-50. doi: 10.1016/j.jaut.2017.09.009. Epub 2017 Sep 27.
6
Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation.将代谢作为自身免疫、炎症和移植的新型治疗方法
J Immunol. 2017 Feb 1;198(3):999-1005. doi: 10.4049/jimmunol.1601318.
7
A guide to immunometabolism for immunologists.免疫学家的免疫代谢指南。
Nat Rev Immunol. 2016 Sep;16(9):553-65. doi: 10.1038/nri.2016.70. Epub 2016 Jul 11.
8
Identification of protein succination as a novel modification of tubulin.鉴定蛋白质琥珀酰化作为微管蛋白的一种新型修饰。
Biochem J. 2014 Sep 1;462(2):231-45. doi: 10.1042/BJ20131581.
9
The succinated proteome.琥珀酰化蛋白质组。
Mass Spectrom Rev. 2014 Mar-Apr;33(2):98-109. doi: 10.1002/mas.21382. Epub 2013 Sep 30.
10
S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate.S-（2-琥珀酰基）半胱氨酸：三羧酸循环中间产物对组织蛋白的一种新型化学修饰
Arch Biochem Biophys. 2006 Jun 1;450(1):1-8. doi: 10.1016/j.abb.2006.03.005. Epub 2006 Mar 22.
Zotero 插件